Clinical Trial Update: Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing abrocitinib to dupilumab in adults with moderate-to-severe atopic dermatitis on topical therapy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Abrocitinib (abrocitinib)
• Dupilumab (dupilumab)

Snippet

Sponsor: Pfizer | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2022-07-08